MHRAsafety guidance72% confidence
Guidance: MHRA Innovation Office
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Eli Lilly.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Diabetes · GLP-1
- Sub-indication
- General
Related signal: Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance